Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors

J. Robert Lane, Pavel Chubukov, Wei Liu, Meritxell Canals, Vadim Cherezov, Ruben Abagyan, Raymond C. Stevens, Vsevolod Katritch

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Small molecules targeting allosteric pockets of G protein-coupled receptors (GPCRs) have a great therapeutic potential for the treatment of neurologic and other chronic disorders. Here we performed virtual screening for orthosteric and putative allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-based models: the receptor with an empty binding pocket (D3R APO), and the receptor complex with dopamine (D3RDopa). Subsequent biochemical and functional characterization revealed 14 novel ligands with a binding affinity of better than 10 μM in the D3RAPO candidate list (56% hit rate), and 8 novel ligands in the D3RDopa list (32% hit rate). Most ligands in the D3RAPO model span both orthosteric and extended pockets and behave as antagonists at D3R, with compound 7 showing the highest potency of dopamine inhibition (IC 50 57 nM). In contrast, compounds identified by the D3R Dopa model are predicted to occupy an allosteric site at the extracellular extension of the pocket, and they all lack the anchoring amino group. Compounds targeting the allosteric site display a variety of functional activity profiles, where behavior of at least two compounds (23 and 26) is consistent with noncompetitive allosteric modulation of dopamine signaling in the extracellular signal-regulated kinase 1 and 2 phosphorylation and β-arrestin recruitment assays. The high affinity and ligand efficiency of the chemically diverse hits identified in this study suggest utility of structure-based screening targeting allosteric sites of GPCRs.

Original languageEnglish (US)
Pages (from-to)794-807
Number of pages14
JournalMolecular Pharmacology
Volume84
Issue number6
DOIs
StatePublished - Dec 2013
Externally publishedYes

Fingerprint

Dopamine Receptors
Allosteric Site
Ligands
Dopamine
G-Protein-Coupled Receptors
Dopamine D3 Receptors
Arrestin
Dihydroxyphenylalanine
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Nervous System
Phosphorylation
Efficiency

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. / Lane, J. Robert; Chubukov, Pavel; Liu, Wei; Canals, Meritxell; Cherezov, Vadim; Abagyan, Ruben; Stevens, Raymond C.; Katritch, Vsevolod.

In: Molecular Pharmacology, Vol. 84, No. 6, 12.2013, p. 794-807.

Research output: Contribution to journalArticle

Lane, JR, Chubukov, P, Liu, W, Canals, M, Cherezov, V, Abagyan, R, Stevens, RC & Katritch, V 2013, 'Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors', Molecular Pharmacology, vol. 84, no. 6, pp. 794-807. https://doi.org/10.1124/mol.113.088054
Lane, J. Robert ; Chubukov, Pavel ; Liu, Wei ; Canals, Meritxell ; Cherezov, Vadim ; Abagyan, Ruben ; Stevens, Raymond C. ; Katritch, Vsevolod. / Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. In: Molecular Pharmacology. 2013 ; Vol. 84, No. 6. pp. 794-807.
@article{0aafaf971b1543169b1eea65a62c1999,
title = "Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors",
abstract = "Small molecules targeting allosteric pockets of G protein-coupled receptors (GPCRs) have a great therapeutic potential for the treatment of neurologic and other chronic disorders. Here we performed virtual screening for orthosteric and putative allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-based models: the receptor with an empty binding pocket (D3R APO), and the receptor complex with dopamine (D3RDopa). Subsequent biochemical and functional characterization revealed 14 novel ligands with a binding affinity of better than 10 μM in the D3RAPO candidate list (56{\%} hit rate), and 8 novel ligands in the D3RDopa list (32{\%} hit rate). Most ligands in the D3RAPO model span both orthosteric and extended pockets and behave as antagonists at D3R, with compound 7 showing the highest potency of dopamine inhibition (IC 50 57 nM). In contrast, compounds identified by the D3R Dopa model are predicted to occupy an allosteric site at the extracellular extension of the pocket, and they all lack the anchoring amino group. Compounds targeting the allosteric site display a variety of functional activity profiles, where behavior of at least two compounds (23 and 26) is consistent with noncompetitive allosteric modulation of dopamine signaling in the extracellular signal-regulated kinase 1 and 2 phosphorylation and β-arrestin recruitment assays. The high affinity and ligand efficiency of the chemically diverse hits identified in this study suggest utility of structure-based screening targeting allosteric sites of GPCRs.",
author = "Lane, {J. Robert} and Pavel Chubukov and Wei Liu and Meritxell Canals and Vadim Cherezov and Ruben Abagyan and Stevens, {Raymond C.} and Vsevolod Katritch",
year = "2013",
month = "12",
doi = "10.1124/mol.113.088054",
language = "English (US)",
volume = "84",
pages = "794--807",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors

AU - Lane, J. Robert

AU - Chubukov, Pavel

AU - Liu, Wei

AU - Canals, Meritxell

AU - Cherezov, Vadim

AU - Abagyan, Ruben

AU - Stevens, Raymond C.

AU - Katritch, Vsevolod

PY - 2013/12

Y1 - 2013/12

N2 - Small molecules targeting allosteric pockets of G protein-coupled receptors (GPCRs) have a great therapeutic potential for the treatment of neurologic and other chronic disorders. Here we performed virtual screening for orthosteric and putative allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-based models: the receptor with an empty binding pocket (D3R APO), and the receptor complex with dopamine (D3RDopa). Subsequent biochemical and functional characterization revealed 14 novel ligands with a binding affinity of better than 10 μM in the D3RAPO candidate list (56% hit rate), and 8 novel ligands in the D3RDopa list (32% hit rate). Most ligands in the D3RAPO model span both orthosteric and extended pockets and behave as antagonists at D3R, with compound 7 showing the highest potency of dopamine inhibition (IC 50 57 nM). In contrast, compounds identified by the D3R Dopa model are predicted to occupy an allosteric site at the extracellular extension of the pocket, and they all lack the anchoring amino group. Compounds targeting the allosteric site display a variety of functional activity profiles, where behavior of at least two compounds (23 and 26) is consistent with noncompetitive allosteric modulation of dopamine signaling in the extracellular signal-regulated kinase 1 and 2 phosphorylation and β-arrestin recruitment assays. The high affinity and ligand efficiency of the chemically diverse hits identified in this study suggest utility of structure-based screening targeting allosteric sites of GPCRs.

AB - Small molecules targeting allosteric pockets of G protein-coupled receptors (GPCRs) have a great therapeutic potential for the treatment of neurologic and other chronic disorders. Here we performed virtual screening for orthosteric and putative allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-based models: the receptor with an empty binding pocket (D3R APO), and the receptor complex with dopamine (D3RDopa). Subsequent biochemical and functional characterization revealed 14 novel ligands with a binding affinity of better than 10 μM in the D3RAPO candidate list (56% hit rate), and 8 novel ligands in the D3RDopa list (32% hit rate). Most ligands in the D3RAPO model span both orthosteric and extended pockets and behave as antagonists at D3R, with compound 7 showing the highest potency of dopamine inhibition (IC 50 57 nM). In contrast, compounds identified by the D3R Dopa model are predicted to occupy an allosteric site at the extracellular extension of the pocket, and they all lack the anchoring amino group. Compounds targeting the allosteric site display a variety of functional activity profiles, where behavior of at least two compounds (23 and 26) is consistent with noncompetitive allosteric modulation of dopamine signaling in the extracellular signal-regulated kinase 1 and 2 phosphorylation and β-arrestin recruitment assays. The high affinity and ligand efficiency of the chemically diverse hits identified in this study suggest utility of structure-based screening targeting allosteric sites of GPCRs.

UR - http://www.scopus.com/inward/record.url?scp=84888883269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888883269&partnerID=8YFLogxK

U2 - 10.1124/mol.113.088054

DO - 10.1124/mol.113.088054

M3 - Article

C2 - 24021214

AN - SCOPUS:84888883269

VL - 84

SP - 794

EP - 807

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -